bioAffinity Technologies, Inc.
BIAFHealthcareNASDAQDiagnostics & Research · Last scanned Sep 7, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, bioAffinity Technologies, Inc. focuses on Diagnostics & Research services and products. bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. With a market capitalization of $9.2M, it sits in micro-cap territory. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services.
Market Cap
$9.2M
Beta
-1.11
P/E (TTM)
—
P/E (Fwd)
-25.45
EPS (TTM)
$-1.35
EPS (Fwd)
$-0.60
ROE
-1860.2%
ROA
-125.1%
Cash
$2.4M
Total Debt
$1.4M
Free CF
-$6.9M
52W Change
-86.2%
Annual Financials
Cash vs Debt
Where BIAF stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BIAF finished 438.67% above its 150-day moving average ($1.81) and 473.53% above its 200-day moving average ($1.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BIAF overbought or oversold?
At the September 3, 2026 close, BIAF's RSI(14) was 88.9, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $2.4M in cash comfortably exceeding the $1.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$6.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -1860.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $5K (2022) to $6.1M (2025), reflecting a 127070% increase over the period.
BIAF's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BIAF.